Ben Auspitz is listed as a director on 15 SEC Form D filings by 6 issuers between Jun 2011 and Aug 2026. Largest by amount reported sold: Compass Therapeutics LLC (Cambridge, MA — biotechnology — 2015–2018; $110.2M reported sold to 20 investors), Unum Therapeutics Inc. (Cambridge, MA — biotechnology — 2014–2015; $104.4M reported sold to 22 investors), Checkmate Pharmaceuticals, Inc. (Cambridge, MA — biotechnology — 2017–2019; $85.1M reported sold to 17 investors), Ultragenyx Pharmaceutical Inc. (Novato, CA — biotechnology — 2011–2012; $75M reported sold to 34 investors), Prana Therapies, Inc. (Encinitas, CA — biotechnology — 2026; $40.2M reported sold to 9 investors) and 1 more (all listed below).
What this means A repeat sponsor — 6 separate companies raised money with this person listed as director, over about 15 years. Across those companies the filings report $420.9M sold in total.
Listed alongside Carl L. Gordon (4 shared filings), Charles Yon (4 shared filings), Corey Goodman (4 shared filings), Errik Anderson (4 shared filings), Michael Powell (4 shared filings) and 48 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Ben. Each name links to their own page.
The issuers belong to 2 sponsor groups: Compass Therapeutics (2 issuers, $170.7M reported sold, 2014–2020) and Antlia (2 issuers, $6.56M reported sold, 2020–2026).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 15 public filings for Ben Auspitz and found 13 differences, 2 worth asking the sponsor about: Form D filed 258 days after the first sale; Ben Auspitz is no longer listed on the Jan 28, 2020 amendment; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.